News and Announcements
Investment platform raises $1m in 6 hours, public offer closes in 6 days
- Published June 22, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Unhedged is an Australian fintech platform that enables retail investors to use complex algorithms to invest in the stock market. Unhedged gives retail investors direct and transparent access to the investment strategies of institutional investors. Unhedged has 4500 people on its waiting list, ready to use the app when it expands from sophisticated investors to retail investors in Q3, 2021. Unhedged met its minimum funding goal of $350,000 within 45 minutes of opening a private offer and raised $1m in 6 hours. The offer is now open to the public and closes in 6 days.
About Unhedged
Unhedged is a super simple app-based experience that allows everyday investors to assign their money to advanced AI trading algorithms to access higher performance. The algorithms are built on known factors but are enhanced by our quant team and made suitable to trade retail funds.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
